Univariate and multivariate regression results for Total Therapy I (TT I, n = 231) combined with the first 231 patients on Total Therapy II (TT II).
| . | % of Patients . | Overall Survival . | . | Event-free Survival . | |
|---|---|---|---|---|---|
| Abbreviations: HR, hazard ratio; CI, confidence interval; P, regression model P-value; NS, not significant; CA, cytogenetic abnormalities; CRP, C-reactive protein; LDH; B2M, beta-2 microglobulin | |||||
| TT I / TT II | HR (95% CI) | P | HR (95% CI) | P | |
| Univariate | |||||
| Total Therapy II | — | 0.8 (0.6, 1.1) | .167 | 0.5 (0.3, 0.6) | <.001 |
| Age ≥ 65 yrs | 9/21 | 1.9 (1.4, 2.8) | <.001 | 1.6 (1.2, 2.2) | .003 |
| Any CA | 32/34 | 2.1 (1.6, 2.8) | <.001 | 1.7 (1.3, 2.2) | <.001 |
| CA13 / hypodiploid | 16/20 | 2.8 (2.0, 3.9) | <.001 | 1.9 (1.4, 2.6) | <.001 |
| CRP ≥ 4 mg/L | 47/56 | 1.8 (1.3, 2.3) | <.001 | 1.6 (1.3, 2.1) | <.001 |
| LDH ≥ 190 IU/L | 21/22 | 2.0 (1.5, 2.7) | <.001 | 1.6 (1.2, 2.1) | |
| B2M ≥ 4 mg/L | 30/29 | 1.9 (1.4, 2.5) | <.001 | 1.8 (1.4, 2.4) | <.001 |
| Multivariate | |||||
| Total Therapy II | 0.6 (0.4, 0.9) | .012 | 0.4 (0.3, 0.5) | <.001 | |
| Age ≥ 65 yrs | 1.7 (1.2, 2.6) | .005 | 1.7 (1.2, 2.4) | .002 | |
| CA13 / hypodiploid | 2.6 (1.9, 3.6) | <.001 | 1.9 (1.4, 2.6) | <.001 | |
| CRP ≥ 4 mg/L | 1.7 (1.3, 2.3) | <.001 | 1.6 (1.2, 2.1) | <.001 | |
| B2M ≥ 4 mg/L | NS | 1.5 (1.2, 2.0) | .003 | ||
| LDH ≥ 190 IU/L | 1.5 (1.1, 2.1) | .010 | NS | ||
| . | % of Patients . | Overall Survival . | . | Event-free Survival . | |
|---|---|---|---|---|---|
| Abbreviations: HR, hazard ratio; CI, confidence interval; P, regression model P-value; NS, not significant; CA, cytogenetic abnormalities; CRP, C-reactive protein; LDH; B2M, beta-2 microglobulin | |||||
| TT I / TT II | HR (95% CI) | P | HR (95% CI) | P | |
| Univariate | |||||
| Total Therapy II | — | 0.8 (0.6, 1.1) | .167 | 0.5 (0.3, 0.6) | <.001 |
| Age ≥ 65 yrs | 9/21 | 1.9 (1.4, 2.8) | <.001 | 1.6 (1.2, 2.2) | .003 |
| Any CA | 32/34 | 2.1 (1.6, 2.8) | <.001 | 1.7 (1.3, 2.2) | <.001 |
| CA13 / hypodiploid | 16/20 | 2.8 (2.0, 3.9) | <.001 | 1.9 (1.4, 2.6) | <.001 |
| CRP ≥ 4 mg/L | 47/56 | 1.8 (1.3, 2.3) | <.001 | 1.6 (1.3, 2.1) | <.001 |
| LDH ≥ 190 IU/L | 21/22 | 2.0 (1.5, 2.7) | <.001 | 1.6 (1.2, 2.1) | |
| B2M ≥ 4 mg/L | 30/29 | 1.9 (1.4, 2.5) | <.001 | 1.8 (1.4, 2.4) | <.001 |
| Multivariate | |||||
| Total Therapy II | 0.6 (0.4, 0.9) | .012 | 0.4 (0.3, 0.5) | <.001 | |
| Age ≥ 65 yrs | 1.7 (1.2, 2.6) | .005 | 1.7 (1.2, 2.4) | .002 | |
| CA13 / hypodiploid | 2.6 (1.9, 3.6) | <.001 | 1.9 (1.4, 2.6) | <.001 | |
| CRP ≥ 4 mg/L | 1.7 (1.3, 2.3) | <.001 | 1.6 (1.2, 2.1) | <.001 | |
| B2M ≥ 4 mg/L | NS | 1.5 (1.2, 2.0) | .003 | ||
| LDH ≥ 190 IU/L | 1.5 (1.1, 2.1) | .010 | NS | ||